NARI Stock Cash Flow Statements

Inari Medical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Inari Medical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30

cash flows from operating activities
net income	-18,367,000	-31,348,000	-24,202,000	-4,665,000	3,162,000	2,085,000	-2,218,000	-5,798,000	-10,153,000	-10,187,000	-3,129,000	1,107,000	-2,804,000	4,068,000	7,469,000	6,985,000	6,496,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	4,133,000	3,882,000	3,864,000
amortization of deferred financing costs	22,000	21,000	22,000	17,000	10,000	12,000	8,000	35,000	36,000	36,000	36,000	35,000	32,000	40,000	36,000	39,000	29,000
amortization of right-of-use assets	1,251,000	855,000	752,000	746,000	740,000	734,000	1,625,000	647,000	574,000	621,000	604,000	737,000	180,000	180,000	177,000
share-based compensation expense	12,951,000	13,039,000	12,870,000	9,801,000	9,844,000	10,353,000	10,339,000	7,596,000	7,356,000	7,164,000	6,555,000
impairment loss on strategic investment				0
allowance for credit losses	0			-18,000	463,000	-28,000	91,000	395,000	275,000	-13,000	79,000
loss on disposal of fixed assets	324,000	104,000	8,000	46,000	-4,000	4,000	26,000	71,000
impairment of capitalized software development costs
amortization of premium and discount on marketable securities	-740,000	-414,000	-553,000	-1,873,000	-3,295,000	-4,302,000	-3,810,000
change in fair value of contingent consideration liability	6,578,000	5,728,000	6,303,000
changes in:
accounts receivable	-2,788,000	-3,647,000	-8,672,000	512,000	-7,005,000	-7,388,000	2,827,000	-4,810,000	-5,260,000	-4,265,000	-2,695,000	-3,463,000	-7,428,000	-33,000	-3,437,000	-7,156,000	-5,376,000
inventories	-5,457,000	-4,831,000	-2,090,000	359,000	-1,463,000	-2,509,000	-3,825,000	-2,982,000	-3,030,000	-2,888,000	-2,788,000	-1,564,000	-1,401,000	-4,450,000	-3,073,000	-3,402,000	-1,575,000
prepaid expenses, deposits and other assets	-3,045,000	392,000	-625,000	6,443,000	3,942,000	-152,000	504,000	2,117,000	-2,609,000	811,000	261,000	1,095,000	6,781,000	-8,398,000	-2,908,000
accounts payable	-923,000	4,357,000	1,493,000	-2,092,000	2,853,000	-100,000	-317,000	1,581,000	1,319,000	-1,293,000	-467,000	1,472,000	-5,234,000	4,803,000	2,473,000	-486,000	1,239,000
payroll-related accruals, accrued expenses and other liabilities	6,146,000	23,163,000	-953,000	4,625,000	5,051,000	9,954,000	-7,787,000	11,253,000	-1,212,000	6,897,000	-6,247,000	13,073,000	3,123,000	6,161,000	3,635,000
operating lease liabilities	-882,000	-410,000	-505,000	-305,000	-356,000	-309,000	-366,000	-358,000	-21,000	-269,000	-275,000	-198,000	-193,000
lease prepayments for lessor's owned leasehold improvements				0	0	0	-458,000	265,000	-1,534,000	-872,000	-2,097,000	-2,791,000
net cash from operating activities	2,712,000	11,513,000	-12,288,000		15,939,000	9,760,000	-2,013,000	11,255,000	-13,066,000	-3,061,000	-9,100,000	15,007,000	-5,589,000	7,302,000	8,766,000	-1,624,000	5,341,000
capex	-3,707,000	-4,580,000	-1,910,000		-1,608,000	-1,229,000	-964,000	-1,778,000	-2,309,000	-3,119,000	-2,745,000	-2,718,000	0	-4,921,000	-1,265,000	-2,384,000	-1,658,000
free cash flows	-995,000	6,933,000	-14,198,000		14,331,000	8,531,000	-2,977,000	9,477,000	-15,375,000	-6,180,000	-11,845,000	12,289,000	-5,589,000	2,381,000	7,501,000	-4,008,000	3,683,000
cash flows from investing activities
purchases of property and equipment	-2,888,000	-3,761,000	-1,250,000	-909,000	-1,608,000	-1,229,000	-964,000	-1,778,000	-2,309,000	-3,119,000	-2,745,000	-2,718,000
purchases of marketable securities	-52,047,000	-17,537,000	-21,501,000	-11,677,000	-110,331,000	-162,111,000	-122,054,000	-157,502,000	-101,289,000	-118,741,000	-112,073,000
maturities of marketable securities	21,501,000	12,634,000	62,573,000	107,719,000	123,760,000	157,500,000	119,300,000	128,600,000	117,000,000	20,000,000	47,000,000
purchases of other investments				0	0	-240,000	-325,000	-2,567,000	0	0	-5,693,000
working capital adjustment related to acquisition	0
capitalized software development costs	-819,000	-819,000	-660,000
net cash from investing activities	-34,253,000	-5,761,000	39,162,000	-59,716,000	11,821,000	-6,080,000	-4,043,000	-33,247,000	13,402,000	-101,860,000	-73,511,000	-2,657,000	-7,428,000	-18,426,000	-22,511,000	-52,361,000	-1,658,000
cash flows from financing activities
proceeds from issuance of common stock under employee stock purchase plan	5,281,000	0	3,983,000	1,000	5,748,000	0	4,172,000	0	4,995,000	0	3,427,000	0	3,676,000	0	1,882,000
proceeds from exercise of stock options	117,000	98,000	145,000	277,000	107,000	214,000	226,000		109,000	156,000	345,000		159,000	192,000	381,000		159,000
payment of taxes related to vested equity awards	-3,012,000	-2,851,000	-3,113,000
net cash from financing activities	2,386,000	-2,753,000	1,015,000	-2,410,000	3,467,000	-2,352,000	2,466,000	-1,689,000	3,880,000	-1,595,000	176,542,000	-620,000	2,993,000	-514,000	2,214,000	226,000	-30,531,000
effect of foreign exchange rate changes on cash, cash equivalents and restricted cash	171,000	-14,000	110,000
net increase in cash, cash equivalents and restricted cash	-28,984,000	2,985,000	27,999,000
cash, cash equivalents and restricted cash beginning of period	0	0	39,208,000									0	0	0	114,617,000	0	0
cash, cash equivalents and restricted cash end of period	-28,984,000	2,985,000	67,207,000									11,594,000	-10,164,000	-11,581,000	102,903,000	-53,759,000	-26,848,000
deferred income taxes
gain on previously held investment in limflow
net cash provided (used in) by operating activities
sales of marketable securities
net cash paid for acquisition
issuance of common stock in public offering, net of issuance costs of 11.9 million
payment of taxes related to vested restricted stock units				-2,688,000	-2,388,000	-2,566,000	-1,932,000	-1,890,000	-1,224,000	-1,751,000	-1,624,000	-757,000	-842,000	-706,000	-49,000
effect of foreign exchange rate on cash, cash equivalents and restricted cash
net decrease in cash, cash equivalents and restricted cash
cash, cash equivalents and restricted cash beginning of year
cash, cash equivalents and restricted cash end of year
depreciation					1,432,000	1,406,000	1,348,000	1,243,000	1,170,000	1,197,000	1,063,000	926,000	820,000	679,000	609,000	454,000	358,000
proceeds from issuance of common stock in public offering, net of issuance costs of 11.9 million									0	0	174,394,000
effect of foreign exchange rate changes on cash and cash equivalents					118,000
net increase in cash and cash equivalents							-3,660,000
cash and cash equivalents beginning of period					0	0	60,222,000	0	0	0	92,752,000
cash and cash equivalents end of period					31,345,000	1,275,000	56,562,000	-23,306,000	3,804,000	-106,832,000	186,556,000
net decrease in cash and cash equivalents
supplemental disclosures of cash flow information:
cash paid for income taxes						1,333,000	104,000	332,000	788,000	2,208,000	89,000	201,000	113,000	40,000	118,000	72,000	1,000
cash paid for interest						33,000	32,000	39,000	37,000	38,000	37,000	38,000	37,000	39,000	37,000	33,000	348,000
noncash investing and financing:
lease liabilities arising from obtaining new right-of-use assets						0	1,030,000	1,613,000
effect of foreign exchange rate on cash and cash equivalents							-70,000	375,000	-412,000	-316,000	-127,000	-136,000	-140,000	57,000	-183,000
loss on extinguishment of debt																0
loss on change in fair value of warrant liabilities																0	0
proceeds from issuance of common stock in public offering, net of issuance costs
proceeds from exercise of stock options and warrants
proceeds from notes payable																0	0
repayments of notes payable																0
debt financing costs																10,000	-440,000
net increase in cash											93,804,000	11,594,000	-10,164,000	-11,581,000	-11,714,000	-53,759,000	-26,848,000
common stock issued on conversion of convertible preferred stock																0	0
common stock warrants issued on conversion of preferred stock warrants and the reclassification of the warrant liability																0	0
deferred initial public offering cost recorded to additional paid in capital																0	0
net decrease in cash									3,804,000
amortization of fair value of warrants issued with debt
purchases of short-term investments
maturities of short-term investments
proceeds from issuance of common stock upon initial public offering, net of issuance costs paid																0	0
proceeds from subscriptions receivable
lease liabilities arising from obtaining right-of-use assets
accrual of deferred interest obligation associated with debt
share based compensation expense													12,499,000	4,604,000	3,836,000	1,565,000	959,000
benefit from doubtful accounts													0	-161,000	139,000		-69,000
purchases of marketable security investments
maturities of marketable security investments
proceeds from exercise of warrants
purchase of property and equipment														-4,921,000	-1,265,000	-2,384,000	-1,658,000
purchase of short-term investments														-63,505,000	-21,246,000
maturity of short-term investments
lease liabilities															-190,000
proceeds from issuance of redeemable convertible preferred stock, net of offering costs paid
proceeds from exercise of stock option and warrants
prepaid expenses and other assets																	446,000
payroll-related accruals, accrued liabilities and other liabilities																	2,186,000
proceeds from warrants exercises																	0

We provide you with 20 years of cash flow statements for Inari Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Inari Medical stock. Explore the full financial landscape of Inari Medical stock with our expertly curated income statements.

The information provided in this report about Inari Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.